AS01E-adjuvanted RSV pre-F protein vaccine in adults with lung or kidney transplant: a phase 2b randomized trial
-adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) over 12 months in kidney or lung transplant recipients ≥18 years, randomized 1:1 to receive one (n = 131) or two doses 30-60 days apart (n = 130). A control group of non-immunocompromised adults ≥50 years (n = 125) received a single dose. The primary outcome was the mean geometric increase in RSV-A and RSV-B neutralizing titers one month following a second adjuvanted RSVPreF3 dose relative to the first dose in transplant recipients. Secondary outcomes included assessment of the safety and immunogenicity of adjuvanted RSVPreF3 in transplant recipients compared with the control group. In transplant recipients receiving two doses, neutralizing titers against RSV-A and RSV-B were numerically higher one month post-dose 2 than post-dose 1 (mean geometric increases: 1.34 [95% CI: 1.20, 1.48] for RSV-A [n = 111] and 1.26 [95% CI: 1.14, 1.40] for RSV-B [n = 111]). A single dose was immunogenic in transplant recipients, but showed slower and generally lower initial neutralizing responses than in non-immunocompromised controls, specifically in individuals receiving mycophenolate. RSVPreF3-specific CD4 + T-cell frequencies increased after vaccination versus baseline in all groups. Humoral and cell-mediated immune responses remained above baseline for 12 months post-vaccination. Both doses of adjuvanted RSVPreF3 were well tolerated and had a similar and acceptable safety profile. Overall, these results support a favorable benefit-risk profile of adjuvanted RSVPreF3 in kidney and lung transplant recipients.
Authors
- Michael D. Nissen (ORCID: https://orcid.org/0000-0003-1686-3313)
- Corinne Vandermeulen (ORCID: https://orcid.org/0000-0002-1954-7554)
- Vera Paloschi (ORCID: https://orcid.org/0000-0002-7745-1809)
- Hristos Karakizlis (ORCID: https://orcid.org/0000-0001-5190-7778)
- Dominique Descamps
- Marie‐Pierre David (ORCID: https://orcid.org/0000-0002-8670-2366)
- Pyoeng Gyun Choe (ORCID: https://orcid.org/0000-0001-6794-7918)
- Ana Isabel Sánchez-Fructuoso (ORCID: https://orcid.org/0000-0001-7017-9729)
- Veronica Hulstrøm (ORCID: https://orcid.org/0009-0003-0400-8026)
- Shigeyoshi Yamanaga (ORCID: https://orcid.org/0000-0002-4372-0011)
- Kemi Oluwayi (ORCID: https://orcid.org/0009-0000-6832-7753)
- Deepali Kumar (ORCID: https://orcid.org/0000-0003-1961-0477)
- Steven James Chadban (ORCID: https://orcid.org/0000-0002-0527-898X)
- Anum Abbas (ORCID: https://orcid.org/0000-0001-5891-2019)
- Hiwot Amare Hailemariam
- Catherine M. Gerard (ORCID: https://orcid.org/0000-0002-9915-4477)
- Catherine Small
- Virginia Luz Pérez González
- On behalf of the RSV OA=ADJ-023 Study Group
Institutions
- Universidad Complutense de Madrid (ES)
- The University of Sydney (AU)
- University Health Network (CA)
- The University of Queensland (AU)
- GlaxoSmithKline (United Kingdom) (GB)
- Justus-Liebig-Universität Gießen (DE)
- Royal Brisbane and Women's Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Seoul National University Hospital (KR)
- Hospital Clínico San Carlos (ES)
- GlaxoSmithKline (Belgium) (BE)
- Hospital Universitario 12 De Octubre (ES)
- Japanese Red Cross Kumamoto Hospital (JP)
- Prince Charles Hospital (AU)
- IRCCS Ospedale San Raffaele (IT)
- Prince Charles Hospital (GB)
- Weill Cornell Medicine (US)
- GlaxoSmithKline Research & Development Limited (United Kingdom) (GB)
- Metro North Hospital and Health Service (AU)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41467-026-78584-9
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Moderna